

1 **Title: Retinal pigment epithelial cells reduce vascular leak and proliferation in**  
2 **retinal neovessels**

3 **Short title: RPE cells reduce vascular leak in retinal neovessels**

4 Simone Tzaridis<sup>1,2</sup>, Edith Aguilar<sup>2</sup>, Michael I Dorrell<sup>1,3</sup>, Martin Friedlander<sup>1,2</sup>, Kevin T  
5 Eade<sup>1,2</sup>

6 <sup>1</sup> The Lowy Medical Research Institute, La Jolla, California, USA

7 <sup>2</sup> Department of Molecular Medicine, The Scripps Research Institute, La Jolla,  
8 California, USA

9 <sup>3</sup> Point Loma Nazarene University, San Diego, California, USA

10

11

12

13

14

15

16

17

18

19

20 **Abstract**

21 Retinal pigment epithelial (RPE)-cells possess numerous functions and may respond to  
22 stress and damage of the neuroretina. In different neurodegenerative diseases,  
23 including age-related macular degeneration (AMD), retinitis pigmentosa, and macular  
24 telangiectasia type 2 (MacTel), RPE-cells have been shown to proliferate and migrate  
25 into the neuroretina, forming intraretinal pigment plaques. Though pigmentary changes  
26 are associated with disease progression, it is not known if their presence is protective or  
27 detrimental. In this study, we evaluated the impact of pigment plaques on vascular  
28 changes and disease progression in patients with macular telangiectasia type 2  
29 (MacTel), an example of a progressive neurodegenerative retinal disease. We then  
30 studied underlying pathomechanisms using a mouse model mirroring these changes,  
31 the very-low-density lipoprotein receptor mutant (*Vldlr*<sup>-/-</sup>) mouse.

32 In a retrospective, longitudinal study, we analyzed multimodal retinal images of patients  
33 with MacTel and showed that pigment plaques were associated with a decrease in  
34 vascular leakage and stabilized neovascular growth. Using genetic approaches, we  
35 analyzed changes in expression levels of relevant genes in the RPE and retinas of  
36 *Vldlr*<sup>-/-</sup> mice during RPE-proliferation and migration. Our data indicated that RPE-cells  
37 transitioned from an epithelial to a mesenchymal state (“epithelial-mesenchymal  
38 transition”, EMT), proliferated and accumulated along neovessels. Using dextran  
39 angiography and immunofluorescence, we demonstrated that the perivascular  
40 accumulation of RPE-cells reduced vascular leakage. Pharmacologic inhibition of EMT  
41 led to a decrease in pigment coverage and exacerbation of neovascular growth and  
42 exudation.

43 Our findings indicate that the proliferation, migration and perivascular accumulation of  
44 RPE-cells may stabilize vascular proliferation and exudation, thereby exerting a  
45 protective effect on the diseased retina. We conclude that interfering with this “natural  
46 repair mechanism” may have detrimental effects on the course of the disease and  
47 should thus be avoided.

48

49

50

51

52

53

54

## 55 **Introduction**

56 Retinal pigment epithelial (RPE)-cells possess numerous functions and may respond to  
57 stress and damage of the neuroretina.[1] In different neurodegenerative diseases,  
58 including age-related macular degeneration (AMD), retinitis pigmentosa, and macular  
59 telangiectasia type 2 (MacTel), RPE-cells have been proposed to proliferate and  
60 migrate into the neuroretina, forming intraretinal pigment plaques.[2-5] Increasing  
61 evidence suggests that during this process, RPE-cells transition from an epithelial to a  
62 mesenchymal state (“epithelial-mesenchymal transition”, EMT), granting these cells  
63 mesenchymal properties such as the ability to proliferate and migrate.[6, 7] Though  
64 pigmentary changes are commonly associated with disease progression, their role is  
65 not fully understood. This association could represent a causative relationship whereby  
66 the pigmentary changes contribute to disease progression, pigmentary changes could  
67 be protective from worsening disease, or pigmentation could simply be an effect of other  
68 disease-causing retinal changes that are unrelated to disease progression.

69 MacTel is an example of a progressive, neurodegenerative retinal disease that affects  
70 the central retina. Secondary vascular alterations are commonly observed.[8] Pigment  
71 plaques are a frequent finding in MacTel and pigmented changes and vascular  
72 alterations have been found to collocate.[3, 5] Early vascular changes of the disease  
73 include telangiectasia and increased vascular leakage, indicating a dysfunctional inner  
74 blood-retina barrier.[8] With disease progression, a shift of vessels from the deep retinal  
75 plexus to the outer retina as well as the formation of retinal-choroidal anastomoses and  
76 outer retinal neovascularization has been described. These changes may precede the  
77 formation of vision-threatening exudative subretinal neovascularization in some

78 cases,[9-12] and the origin of neovessels has been ascribed to the retinal rather than  
79 the choroidal vasculature.[13-16] Recent imaging studies in MacTel proposed that the  
80 formation of outer retinal neovascularization induced proliferation of the RPE, upon  
81 contact between the RPE and outer retinal vessels.[17] It has been supposed that RPE  
82 cells then use these abnormal vessels as a scaffolding to migrate into inner retinal  
83 layers, where they form dense pigmented plaques.[5] Their role during disease  
84 progression and their impact on vascular changes, including vascular leakage and  
85 proliferation, have not yet been evaluated. We hypothesized that the perivascular  
86 accumulation of RPE-cells may stabilize vascular proliferation and reduce vascular  
87 permeability.

88 The very-low-density lipoprotein receptor (Vldlr) mutant (Vldlr<sup>-/-</sup>) mouse represents a  
89 common model of subretinal neovascularization, and is used to study disease  
90 characteristics of MacTel, retinal angiomatous proliferation and other conditions.[18, 19]  
91 As in MacTel, in Vldlr<sup>-/-</sup> mice, neovascular changes originate from the retinal  
92 vasculature. Retinal vessels proliferate, grow to the outer retina, and subsequently form  
93 subretinal neovascularization. As the disease progresses, mice show a proliferation of  
94 RPE cells with accumulation along neovascular tufts, followed by the migration of  
95 pigmented cells along retinal vessels into the neuroretina.[18, 20, 21] These events  
96 mirror the key neovascular and pigmentation-related events observed in MacTel and  
97 other diseases with subretinal neovascularization, making the Vldlr<sup>-/-</sup> mouse an ideal  
98 model to study these changes.

99 In this study, we aimed to (I) evaluate the role of pigment plaques on vascular changes  
100 and disease progression in MacTel, and (II) study underlying disease mechanisms  
101 using the Vldlr<sup>-/-</sup> mouse model mirroring these changes.

102 First, we show in a longitudinal, retrospective study of eyes with MacTel that  
103 perivascular pigment accumulation was associated with reduced vascular leakage and  
104 decreased *de novo* formation of exudative neovascularization. We then explored  
105 whether the observed associations were causally related and which mechanisms led to  
106 perivascular pigment accumulation in Vldlr<sup>-/-</sup> retinas. We found an enrichment of EMT-  
107 inducers and key mesenchymal markers in the RPE of Vldlr<sup>-/-</sup> mice. Pharmacologic  
108 inhibition of EMT-inducers led to decreased perivascular pigment accumulation and  
109 enhanced neovascular growth and exudation in the Vldlr<sup>-/-</sup> model, indicating a  
110 protective effect of pigmentary changes on vascular proliferation, mitigating vascular  
111 leak and proliferation. Based on our findings, we propose that EMT of the RPE, followed  
112 by proliferation, migration and perivascular accumulation may function as a “natural  
113 repair mechanism”, exerting beneficial, anti-angiogenic and anti-exudative effects on the  
114 diseased retina. As such, we conclude that interfering with these mechanisms may have  
115 detrimental effects on the course of the disease and should thus be avoided.

## 116 **Results**

117 *Perivascular accumulation of pigment is associated with decreased vascular leakage in*  
118 *eyes with MacTel.* To investigate the impact of perivascular pigment accumulation on  
119 vessel leakage and proliferation in MacTel, we compared the longitudinal courses of  
120 eyes with and eyes without pigment plaque *de novo* formation. A total of 1216 eyes  
121 from 608 patients of 12 study centers were evaluated. 69 eyes from 69 patients (mean

122 age 61.9 (range 53-71) years) were included and reviewed over a mean period of 41.6  
123 months (range 24-60). 35 eyes (51%) showed a *de novo* development of pigmentary  
124 changes, and 34 eyes did not. Pigment plaques predominantly accumulated along  
125 vessels within the temporal parafovea (ETDRS subfield 5), usually sparing the fovea  
126 (Additional figure 1). Rarely, an extension of changes to the superior, inferior, or nasal  
127 parafovea (ETDRS subfields 2, 4, 3) was observed.

128 Longitudinal courses of eyes developing pigmented lesions differed from those without.  
129 A decrease in fluorescein leakage and stabilization of vessel proliferation was noted in  
130 all but one eye with pigment plaques. The observed effects were, however, focal and  
131 limited to vessels covered with pigment. In these eyes, vessels lacking pigment plaques  
132 showed stable, or rarely, increased leakage (observed in the nasal parafovea (ETDRS  
133 subfield 3) of 4/35 eyes; see figure 1). Notably, coverage of vessels with pigment was  
134 associated with a decrease in fluorescein leakage both in the early and late phase of  
135 fundus fluorescein angiography (FFA), suggesting a sealing rather than a mere  
136 shadowing effect associated with perivascular pigment accumulation. In eyes without  
137 pigmentary changes, an increase in vascular leakage (in 16/34 eyes [47%]) or stable  
138 leakage (in 18/34 eyes [53%]; table 1) was observed. Proliferation of vessels and  
139 increase in leakage were primarily observed within the temporal parafovea (ETDRS  
140 subfield 5). Exemplary longitudinal courses are illustrated in figures 1 and 2.

141 Exudative subretinal neovascularization is considered a severe, vision-threatening  
142 complication of MacTel, and is associated with severe vascular leakage. The *de novo*  
143 formation of exudative subretinal neovascular membranes was less frequently observed  
144 in eyes with compared to eyes without pigment plaques (in 1/35 [3%] eyes vs 7/34

145 [21%]; Fisher's exact test,  $p=0.0275$ ). Table 1 gives an overview of the clinical findings  
146 in this study cohort.

147 In summary, patients with MacTel showed (I) an accumulation of pigment plaques along  
148 abnormal retinal and subretinal vessels, (II) a decrease in vascular leakage that was  
149 associated with the development of pigment plaques, and (III) a decrease in exudative  
150 subretinal neovascularization associated with the presence of pigment plaques. Based  
151 on our findings in patients with MacTel, we hypothesized that (I) proliferating vessels  
152 may trigger the proliferation and perivascular accumulation of pigment. (II) Pigment  
153 plaques may be formed by RPE cells that undergo EMT, proliferate, migrate and  
154 accumulate along proliferating vessels. (III) Perivascular pigment plaques may decrease  
155 vascular leakage and stabilize vessel proliferation, thus having a beneficial effect on the  
156 diseased retina.

157 To test these hypotheses, and to further evaluate disease mechanisms leading to  
158 perivascular pigment accumulation, we studied related changes in the *Vldlr*<sup>-/-</sup> mouse  
159 model. Similar to eyes with MacTel, the *Vldlr*<sup>-/-</sup> mouse model shows a proliferation of  
160 retinal vessels, formation of retinal-choroidal anastomoses and subretinal  
161 neovascularization. With disease progression, RPE-cells proliferate and accumulate  
162 along subretinal neovessels, and subsequently migrate along retinal vessels into the  
163 neuroretina.[18, 19, 21]

164 *Proliferating retinal vessels trigger perivascular pigment accumulation.*

165 We first set out to investigate whether vascular proliferation triggers the proliferation and  
166 perivascular accumulation of pigment. In the *Vldlr*<sup>-/-</sup> mouse model, retinal vessels begin



167 proliferating around P12, followed by the growth of retinal vessels to the outer retina,  
168 and the formation of subretinal neovascular complexes around P16-P21.[22] RPE-cells  
169 start proliferating around 4 weeks of age, accumulate along neovessels in the subretinal  
170 space, and subsequently migrate along retinal vessels into the neuroretina.[19, 21, 23]  
171 By inhibiting vascular proliferation using neutralizing antibodies against vascular  
172 endothelial growth factor (VEGF), we found a reduction in neovascular tuft formation.  
173 The ratio of pigmented to non-pigmented neovessels was, however, unchanged, and  
174 pigment plaques only developed along proliferating neovessels (see Figure 3A),  
175 suggesting that neovessels precede and are required for pigment plaque formation.

176 *Pigment plaques are formed by RPE cells in Vldlr<sup>-/-</sup> retinas and express similar markers*  
177 *as observed in eyes with MacTel*

178 Previous findings in postmortem retinal samples of eyes with MacTel or retinitis  
179 pigmentosa indicated that intraretinal pigment plaques originated from the RPE.[3]  
180 Intraretinal lesions were found to express the epithelial cell marker cytokeratin-18 (CK-  
181 18), that is specific to RPE-cells in the retina, but were negative for RPE65. Markers for  
182 mesenchymal cells (alpha-smooth muscle actin [α-SMA]) and macrophages/ microglia  
183 (IBA1) were also evaluated, but found to be absent.[3] To verify these findings in the  
184 Vldlr<sup>-/-</sup> mouse model, we evaluated similar markers as previously described.[3]  
185 Proliferating RPE cells within the subretinal space expressed CK-18 and RPE65. Some,  
186 but not all of these cells also showed immunoreactivity for α-SMA (see Additional figure  
187 2), indicating EMT of the RPE. Intraretinal pigment plaques, on the other hand,  
188 expressed CK-18, but neither RPE65 nor IBA1 were detected (Additional figures 2 and  
189 3). The expression of α-SMA was observed in single intraretinal pigmented lesions. The

190 latter were, however, overall smaller and less dense compared to lesions lacking a-SMA  
191 expression, indicating a transitional, possibly less mature stage of these lesions  
192 (Additional figure 2).

193 *RPE-cells undergo EMT in Vldlr<sup>-/-</sup> retinas.*

194 Under physiologic conditions, the RPE is formed by a monolayer of polarized cells.  
195 Disintegration of the RPE monolayer and proliferation and migration of RPE-cells have  
196 been described in different degenerative retinal diseases, and have been attributed to  
197 RPE cells transitioning from an epithelial to a mesenchymal state.[7] To test whether  
198 RPE cells underwent EMT in the Vldlr<sup>-/-</sup> mouse model, we compared gene expression  
199 levels of known EMT-related genes in the RPE of Vldlr<sup>-/-</sup> mice and control Vldlr<sup>+/-</sup>  
200 littermates at P42. At this timepoint, RPE cells have been shown to proliferate and  
201 accumulate along subretinal neovessels and start migrating along retinal vessels into  
202 the neuroretina.[18, 19, 21] Using qPCR arrays, we found an enrichment of genes  
203 coding for EMT pathways (SNAIL1/2) and different mesenchymal markers (vimentin,  
204 fibronectin, N-cadherin) in the RPE of Vldlr<sup>-/-</sup> mice. Genes coding for epithelial markers  
205 (beta-catenin, E-cadherin, zonula occludens-1 [ZO-1]), on the other hand, were  
206 decreased (Figure 3B), indicating that RPE cells underwent EMT in this model.

207 Next, we tested mRNA expression levels of known inducers of EMT in the retinas and  
208 RPE of Vldlr<sup>-/-</sup> mice. The highest differences between Vldlr<sup>-/-</sup> and heterozygous control  
209 littermates were found in fibroblast growth factor-2 (FGF2), which was increased 4-fold,  
210 and in tumor-necrosis factor-alpha (TNF $\alpha$ ), which was increased 2.5-fold. FGF2 is a  
211 known driver of EMT that, among other factors, has been described to play a role in  
212 inducing EMT in RPE cells in proliferative vitreoretinopathy (PVR)[24]. FGF2 is also

213 known to play a role in inducing subretinal fibrosis, and has been shown to have pro-  
214 angiogenic properties.[25, 26] TNF $\alpha$  is a proinflammatory cytokine and a known inducer  
215 of EMT in RPE cells.[7, 27] Elevated levels of TNF $\alpha$  have been detected in vitreous  
216 samples and epiretinal membranes of patients with PVR[28].[27, 29] *In vitro*, TNF $\alpha$  has  
217 been shown to induce RPE cells to upregulate EMT markers and mesenchymal key  
218 molecules.[30] Increased expression levels of TNF have previously been found in the  
219 retinas of Vldlr $^{-/-}$  mice, and in particular at the level of the deep retinal plexus.[22]  
220 *Perivascular pigment decreases neovascular leakage and proliferation in Vldlr $^{-/-}$  retinas.*  
221 Similar to eyes with MacTel, we found that in the Vldlr $^{-/-}$  mouse model vessels covered  
222 with pigment showed reduced dextran leakage compared to vessels not covered with  
223 pigment (Figure 3C). Perivascular pigment plaques expressed zonula occludens-1 (ZO-  
224 1), indicating the formation of tight junctions around proliferating vessels, thereby  
225 possibly reducing vascular leakage (Figure 3D). Furthermore, on OCT, Vldlr $^{-/-}$  mice  
226 showed hyper-reflective changes at the level of the outer retina/ RPE that resemble  
227 alterations observed in MacTel (Figure 3-E), which have been proposed to represent  
228 outer retinal neovascularization and proliferating RPE-cells.[17] Next, we set out to  
229 investigate whether inhibiting EMT of the RPE may impact neovascular leakage and  
230 proliferation in the Vldlr $^{-/-}$  model. Mice treated with neutralizing antibodies against  
231 FGF2 or TNF $\alpha$  from P21 to P42 showed a significant increase in vascular leakage and  
232 in the size of neovascular complexes at P42 in comparison to IgG-treated control  
233 animals (Figure 4A-C). Vascular leakage and perivascular pigment accumulation  
234 showed a negative correlation in both treated and control animals (Figure 4D).

235 To test whether the observed morphological changes were associated with the inhibition  
236 of EMT, we compared gene expression levels of EMT-related genes in the RPE of  
237 *Vldlr*<sup>-/-</sup> mice treated with FGF2, TNF $\alpha$  or control IgG. While no changes were observed  
238 for EMT pathways, genes coding for epithelial markers were enriched, and  
239 mesenchymal markers were decreased in animals treated with FGF2 or TNF $\alpha$ ,  
240 indicating the inhibition of EMT (Figure 4E).

241 In summary, we suggest that the perivascular accumulation of RPE-cells may stabilize  
242 neovascular proliferation and leakage, thereby exerting a beneficial, protective effect on  
243 the diseased retina. Figure 5 summarizes the herein proposed mechanisms in a  
244 schematic illustration.

## 245 **Discussion**

246 Pigment plaques can be found in different retinal diseases involving vascular pathology  
247 and neurodegeneration. The origin of these changes has been attributed to RPE-cells,  
248 accumulating along subretinal and retinal vessels, and migrating along vascular  
249 structures into the neuroretina.[3, 20] The role these changes may play during disease  
250 progression is, however, not yet understood. In this study, we sought to evaluate the  
251 impact of perivascular pigment plaques on the progression of vascular changes in eyes  
252 with MacTel. We observed an association of perivascular pigment with a focal decrease  
253 in vessel permeability, and stabilization of vessel proliferation. The development of  
254 exudative subretinal neovascular complexes was observed less frequently in eyes with  
255 compared to eyes without pigment plaque formation. In the literature, differing numbers  
256 describing potential associations of pigment plaques with subretinal neovascularization  
257 in MacTel have been reported. While Leung et al. found that in about 25% of

258 neovascular eyes, subretinal neovascularization coincided with or preceded pigmentary  
259 changes[5], Engelbrecht et al observed that pigmented lesions preceded the  
260 development of neovascular membranes in all cases (in 11/11 eyes).[14] Meleth et al  
261 reported the *de novo*-development of neovascularization in equal numbers of eyes with  
262 and without preexistent pigmentations, respectively.[31] Differences between our data  
263 and previous reports may be explained by differing definitions of “neovascularization”  
264 and “exudation”, based on distinct imaging modalities, and differing in- and exclusion  
265 criteria, resulting in study populations with varying disease stages, baseline  
266 characteristics and observational periods. More recent studies evaluating longitudinal  
267 OCT-A data found that the formation of outer retinal neovascularization preceded  
268 perivascular pigment accumulation in all cases.[32] Based on their findings on  
269 multimodal retinal imaging, Mueller et al suggested that outer retinal neovascularization  
270 induced proliferation of the RPE, once retinal vessels get in contact with the RPE[17], a  
271 finding that is similar to previous observations in Vldlr<sup>-/-</sup> mice and other models.[18, 19,  
272 21, 33] Our results are in line with these later findings of neovascularization preceding  
273 pigmentation and indicate that perivascular pigment accumulation is a focal process,  
274 possibly triggered by vascular leakage and proliferation, and may represent a “repair  
275 mechanism” of the disrupted RPE. Furthermore, our results may indicate that pigment  
276 plaques could be used as a biomarker to predict neovascular exudation and vascular  
277 stabilization, respectively. Prospective, longitudinal studies are needed to verify our  
278 findings.

279 The reason why only a subset of MacTel patients develop pigment plaques currently  
280 remains obscure and warrants further studies. Limited observational periods and patient

281 numbers might have confounded our findings, representing potential limitations of this  
282 study.

283 To study underlying disease mechanisms, we evaluated related pigmentary and  
284 vascular changes in the Vldlr<sup>-/-</sup> mouse model. We showed that perivascular pigment  
285 plaques expressed similar markers as previously described in postmortem retinal  
286 specimens of eyes with MacTel and other diseases, verifying that these changes are  
287 formed by RPE-cells.[3, 20] We confirmed that pigment accumulation was associated  
288 with a decrease in vessel leakage in the Vldlr<sup>-/-</sup> model. Our findings indicate that  
289 perivascular pigment plaques may form tight junctions around proliferating vessels, as  
290 indicated by ZO-1 localization, thereby reducing vascular leakage and stabilizing  
291 neovascular growth. A similar effect of pigment plaques on vessel permeability has  
292 been previously reported by Jaissle et al, where migrating RPE-cells were observed to  
293 form tight junctions with vascular endothelial cells, thus sealing retinal vessels in a  
294 mouse model for retinitis pigmentosa.[33]

295 While dense pigment plaques within the neuroretina and subretinal space of Vldlr<sup>-/-</sup>  
296 mice showed a focal expression of ZO-1, genes coding for the same epithelial cell  
297 marker were downregulated in the RPE of Vldlr<sup>-/-</sup> mice, indicating a broader loss of cell-  
298 cell contacts and epithelial cell state. This suggests a loss of adhesion in the general  
299 RPE monolayer, perhaps indicative of cells undergoing transition to a more migratory  
300 phenotype. Taken together, these findings might indicate that RPE-cells undergo EMT,  
301 proliferate and accumulate along subretinal and retinal vessels. Once migrating RPE-  
302 cells have found their new position, they may develop cell-cell contacts with neighboring  
303 RPE-cells, forming dense plaques around the vessels, and possibly transition back to

304 an epithelial state (“mesenchymal-epithelial transition”, MET). Similar mechanisms have  
305 been previously described to occur during cancer metastasis and organ  
306 morphogenesis.[34, 35] The hypothesis that RPE cells undergo EMT, followed by MET,  
307 in the *Vldlr*<sup>-/-</sup> model is further supported by the differences we found in the expression  
308 of epithelial and mesenchymal markers in *Vldlr*<sup>-/-</sup> mice compared to previous reports in  
309 MacTel. In MacTel, intraretinal pigment plaques were found to only express the  
310 epithelial marker CK18, while lacking any mesenchymal markers.[3] In the *Vldlr*<sup>-/-</sup>  
311 model, on the other hand, we observed that single intraretinal pigmented lesions also  
312 expressed mesenchymal markers, possibly indicating the presence of different stages  
313 of lesions. This was particularly the case for lesions that were less dense, and thus  
314 possibly less mature, indicating that some RPE-cells were still in a mesenchymal state,  
315 before undergoing MET and forming dense, mature plaques around the vessels. In  
316 MacTel, on the other hand, intraretinal pigment plaques usually develop within months  
317 and may form and progress over the course of several years, forming dense, organized  
318 clusters of pigment around vessels.[3, 5] Thus, it is conceivable that lesions, once  
319 clinically detectable, are overall more mature, and RPE-cells within dense plaques no  
320 longer possess mesenchymal properties, possibly having transitioned back to an  
321 epithelial state. Future studies are warranted to further explore the proposed  
322 mechanisms.

323 EMT of RPE-cells has been described in different ocular conditions[7] and various  
324 inducers of EMT have previously been discussed.[7, 25, 29, 30] In the RPE of *Vldlr*<sup>-/-</sup>  
325 mice, we found several known drivers of EMT to be enriched, with FGF2 and TNF $\alpha$   
326 being the most significant ones in our model. While these factors could be related to

327 general neovascularization events in the Vldlr<sup>-/-</sup> retina, it is important to note that their  
328 inhibition actually reduced neovascularization and leakage, thus indicating a role in EMT  
329 rather than general neovascularization. Other known drivers of EMT and/or fibrosis  
330 have previously been identified in the Vldlr<sup>-/-</sup> model.[36, 37] Notably, EMT and TNF $\alpha$ /  
331 NF $\kappa$ B pathways were previously found to be among the most significantly enriched  
332 gene sets in RPE cells differentiated from induced pluripotent stem cells from MacTel  
333 donors.[38] This underlines the clinical relevance and applicability of our findings in the  
334 Vldlr<sup>-/-</sup> model.

335 Inhibiting EMT in the Vldlr<sup>-/-</sup> model resulted in increased neovascular growth and  
336 exudation, confirming the beneficial effect of perivascular pigment accumulation we had  
337 clinically observed in patients with MacTel. Pigment plaques, on the other hand, have  
338 been shown to be associated with a focal loss in retinal sensitivity (“absolute scotomas”  
339 on fundus-controlled perimetry)[8, 39] and the pigment area with a decrease in visual  
340 acuity in patients with MacTel[5], thus representing a mixed blessing.

341 Intravitreal VEGF inhibitors have been successfully used to treat numerous retinal  
342 diseases showing vascular involvement. In MacTel, VEGF inhibitors have been  
343 effectively applied in eyes showing subretinal neovascularization[40], while no functional  
344 improvement has been reached in non-neovascular eyes.[41] The latter showed,  
345 however, a (temporary) decrease in fluorescein leakage during treatment, followed by  
346 an increase in leakage once treatment had been discontinued.[41] Notably, treated eyes  
347 developed excessive pigmentation and fibrosis later on.[41, 42] In the Vldlr<sup>-/-</sup> model, we  
348 found that perivascular pigment only developed when vascular proliferation was present  
349 and pigment plaques only developed along proliferating vessels. Taken together, this



350 might further indicate that interfering with the herein proposed natural “repair  
351 mechanism” of the diseased retina/RPE, by suppressing either EMT or vascular  
352 leakage/ intraretinal proliferation, may have detrimental effects and thus should be  
353 avoided in MacTel and related diseases.

#### 354 **Conclusions:**

355 In summary, we showed that perivascular pigment accumulation is associated with a  
356 decrease in vascular leakage and stabilization of neovascular growth in proliferative  
357 retinal diseases, such as MacTel, and respective animal models. We revealed  
358 underlying mechanisms leading to perivascular pigment accumulation, and discussed  
359 beneficial effects, changing our current understanding of these changes. Knowledge  
360 about pathophysiological mechanisms is crucial for understanding the disease course  
361 and developing therapeutic interventions as well as choosing appropriate timepoints for  
362 treatment. We conclude that interfering with this “natural repair mechanism” of the  
363 diseased RPE may have detrimental effects on the course of the disease and should  
364 thus be avoided.

#### 365 **Materials and Methods**

366 **Participants.** In a retrospective, longitudinal approach, imaging data of affected  
367 participants from twelve participating sites of the multi-center Natural History Study of  
368 Macular Telangiectasia (MacTel Study) were evaluated. Protocol details of this study  
369 have been published previously.[43] The diagnosis of MacTel type 2 was based on  
370 characteristic morphologic findings on funduscopy, OCT, fundus autofluorescence and  
371 fluorescein angiography[8], and was confirmed by the Moorfields Eye Hospital Reading

372 Centre, London, UK. Patients underwent annual study visits, and eyes were reviewed  
373 over a minimum observational period of 24 months. The studies were approved by the  
374 local ethics committees at each participating study site and were in adherence with the  
375 Declaration of Helsinki. All participants provided informed consent. Data were collected  
376 at a minimum of two time points (at baseline and last available follow up visits), and  
377 sites were selected based on the availability of longitudinal imaging data, including color  
378 fundus photography (CFP), Spectral Domain-OCT (SD-OCT; volume scans of 15° x 10°  
379 (high resolution mode, 97 scans) or 25° x 30° (high speed mode, 61 scans); Spectralis,  
380 Heidelberg Engineering, Heidelberg, Germany), fundus autofluorescence (FA) and  
381 fundus fluorescein angiography (FFA; 30°, centered on the fovea, images taken at 30  
382 seconds, 1, 5 and 10 minutes after fluorescein injection). In a small subset of  
383 participants, OCT-angiography (OCT-A) data were additionally available.

384 Inclusion criteria for this analysis were a confirmed diagnosis of MacTel, a full data set  
385 including the examinations listed above and sufficient image quality. As pigmentary  
386 changes have been shown to only develop in eyes showing disruptions of outer retinal  
387 layers[44], and to ensure equal baseline conditions among both groups, only eyes with  
388 intermediate disease stages were included. The latter was defined as visible disruption  
389 of the ellipsoid zone (EZ)/ photoreceptor layer on OCT, and disease stages 2-3  
390 according to Gass and Blodi.[13] Eyes showing pigment plaques and/ or subretinal/  
391 sub-RPE neovascular membranes (stages 4 and 5 according to Gass and Blodi) at  
392 baseline were excluded. Further exclusion criteria were the presence of potentially  
393 confounding retinal diseases including central serous chorioretinopathy, age-related

394 macular degeneration or diabetic retinopathy, and previous therapies including VEGF-  
395 inhibitors, vitreo-retinal surgery, photodynamic therapy or central laser treatment.

396 Eyes were retrospectively divided into two groups, one group showing a *de novo*  
397 formation of pigment plaques at last follow up, and one group without any pigmentary  
398 changes, and outcome parameters were compared between both groups.

399 Outcome parameters included changes in leakage on FFA (decreased, increased, or  
400 stable leakage within subfields 1-5 of the ETDRS grid) and a *de novo* development of  
401 exudative subretinal neovascular membranes as observed on CFP, OCT, FFA, and  
402 OCT-A (if available).

#### 403 **Image grading and definitions.**

404 **Pigment plaques.** CFP and FA images were analyzed for the presence and position of  
405 pigment plaques at baseline and last follow up.

406 **Leakage on FFA.** On FFA, vessels were graded for an (1) increase, (2) decrease, or  
407 (3) no visible changes in fluorescein leakage at last follow up compared to baseline.

408 Images were evaluated and compared at different time points (at 30 seconds, 1 minute,  
409 and 10 minutes after fluorescein injection) and within subfields 1-5 of the ETDRS grid.

410 **Neovascularization and exudation.** Previously described criteria were applied to  
411 identify neovascular membranes on OCT, FFA, CFP, and OCT-A images (if  
412 available). [16, 44] Neovascular exudation was defined as focal retinal thickening, sub-  
413 or intraretinal fluid, and/or hemorrhages as observed on OCT and/ or CFP in  
414 neovascular eyes.

415 **Animals.** All animal experimental procedures were approved by The Scripps Research  
416 Institute Animal Care and Use Committee. Experiments were performed in accordance  
417 with the NIH Guide for the Care and Use of Laboratory Animals (National Academies  
418 Press, 2011). *Vldlr*<sup>-/-</sup> mice (15) and control littermates (*Vldlr*<sup>+/-</sup> mice) (The Jackson  
419 Laboratory) of up to 12 months of age were used for all animal experiments.

420 **Intravitreal injections.** All intravitreal injections were performed using a Hamilton  
421 syringe and a 34-gauge needle (Hamilton), injecting 1 $\mu$ l of solutions containing  
422 neutralizing antibodies against TNF $\alpha$  (250ng; MAB4101; R&D systems), FGF2 (200ng;  
423 clone bFM-1; 05-117, Millipore Sigma) or VEGF164 (200ng; AF-493-NA; R&D systems).  
424 For each of these antibodies, IgG isotype control antibodies were used as negative  
425 controls (MAB005R, R&D systems; 12-371, Millipore Sigma; AB-108-C, R&D systems).  
426 Intravitreal injections with antibodies against FGF2 or TNF $\alpha$  were performed at P21,  
427 after subretinal neovascular tufts have formed, but before pigmented cells have started  
428 proliferating or migrating[18, 45]. Retinas and RPE/choroid/sclera complexes were  
429 analyzed for gene expression or immunofluorescence at P42. At this timepoint, RPE-  
430 cells have been shown to proliferate and accumulate along subretinal neovessels and  
431 have started migrating into the neuroretina, where they accumulate along retinal  
432 vessels.[18, 19, 21, 45]

433 Intravitreal injections with antibodies against VEGF were performed at P12, when retinal  
434 vessels have started proliferating and anti-VEGF treatment has been shown to be most  
435 effective in this model.[21, 36] Retinas were evaluated at P28 using  
436 immunofluorescence imaging. At this timepoint, the normal RPE monolayer is disrupted,

437 and clumps of RPE cells accumulate along neovascular tufts in the subretinal space of  
438 Vldlr<sup>-/-</sup> mice.[19, 21]

439 **Dextran angiography.** For analyzing vascular leakage, Fluorescein isothiocyanate–  
440 dextran (FITC; 40,000 MW; Sigma-Aldrich) was perfused through the left ventricle of  
441 deeply anesthetized Vldlr<sup>-/-</sup> animals using 150µl of a 50mg/ml solution in PBS.

442 **Immunofluorescence.** Retinas and RPE/choroid complexes were dissected and  
443 prepared for whole mounts or sectioning. For preparation of retinal cross-sections,  
444 isolated eyes were fixed in 4% paraformaldehyde (PFA) for 4 hours, placed in 15%  
445 sucrose overnight at 4°C, followed by 30% sucrose for 2 hours, and embedded in  
446 Tissue-Tek OCT compound (Sakura Finetek) for subsequent cryosectioning. For  
447 preparation of whole mounts, eyes were fixed in 4% PFA for one hour, and  
448 retina/RPE/choroid complexes were dissected and laid flat. Whole-mount  
449 retina/RPE/choroid complexes or cryosections were incubated in blocking buffer (10%  
450 fetal bovine serum and 0.1% Triton X-100 in phosphate-buffered saline [PBS]) at 4°C  
451 for 2 hours, followed by an incubation with primary antibodies in blocking buffer at 4°C  
452 overnight. Specimens were then washed with PBS and incubated with Alexa Fluor–  
453 conjugated secondary antibodies (Thermo Fisher) for 2 hours. Nuclei were stained  
454 using DAPI (Vector Laboratories). Specimen were mounted in Vectashield Plus Antifade  
455 Mounting Medium (Vectorlabs). Primary antibodies against ZO-1 (40-2200, Thermo  
456 Fisher), RPE-65 (PA5-110315, Thermo Fisher), alpha-smooth muscle actin (ab124964,  
457 Abcam), IBA1 (MA5-27726, Thermo Fisher) and Cytokeratin 18 (10830-1-AP,  
458 Proteintech) were used. Endothelial cells were labeled using Fluorescent-conjugated  
459 isolectin Griffonia Simplicifolia IB-4 (GS-Lectin) (I21412, Thermo Fisher). Images were

460 captured with a confocal laser scanning microscope (LSM 710, Zeiss) and processed  
461 with the ZEN 2010 software (Zeiss). The NIH ImageJ software was used for quantifying  
462 dextran-leakage (number of pixels positive for dextran), pigment accumulation (number  
463 of pixels positive for pigment) and neovascular tufts (total numbers of visible tufts per  
464 eye).

465 **Gene expression analyses.** For quantitative polymerase chain reaction (qPCR),  
466 retinas and RPE/choroid complexes were isolated in 500µl Trizol. RNA isolation was  
467 performed using a RNeasy Plus Micro Kit (Qiagen) following the manufacturer's  
468 instructions. 400ng RNA was used for real time-qPCR using the High-capacity cDNA  
469 Reverse transcriptase kit (Thermo Fisher). SYBR Green-based (Thermo Fisher) real-  
470 time quantitative PCR was performed on a QuantStudio 5 (Thermo Fisher) to analyze  
471 mRNA expression levels of various gene products. Expression levels were normalized  
472 to Cyclophilin A. Sequences of primers used are listed in supplementary table 1. Data  
473 were analyzed using the QuantStudio Design and Analysis Software 2.6.0 (Thermo  
474 Fisher).

475 **Statistical analysis.** Statistical analyses were performed using GraphPad Prism,  
476 version 10.1.0 (GraphPad Software, San Diego, CA, USA). Continuous variables were  
477 described by using the mean  $\pm$  standard deviation (SD), median and interquartile range  
478 [IQR] and/ or ranges. Categorical variables were described in terms of frequency.  
479 Unpaired t-test with Welch's correction was applied for comparing parameters between  
480 two groups in normally distributed samples. Mann-Whitney test was used to compare  
481 parameters between two groups in non-normally distributed samples. Kruskal-Wallis  
482 test with Dunn's correction for multiple comparisons was used to compare data between

483 multiple groups. Fisher's exact test was applied to analyze contingency tables with  
484 small sample sizes. Pearson correlation coefficient was calculated to determine linear  
485 correlation between two parameters. Statistical tests applied for each experiment are  
486 detailed in the figure and table legends. A p-value <0.05 was accepted as statistically  
487 significant.

## 488 References

- 489 1. George SM, Lu F, Rao M, Leach LL, Gross JM: The retinal pigment epithelium: Development,  
490 injury responses, and regenerative potential in mammalian and non-mammalian systems. *Prog*  
491 *Retin Eye Res* 2021, 85:100969.
- 492 2. Li ZY, Possin DE, Milam AH: Histopathology of bone spicule pigmentation in retinitis pigmentosa.  
493 *Ophthalmology* 1995, 102(5):805-816.
- 494 3. Yasvoina M, Yang Q, Woods SM, Heeren T, Comer GM, C AE, Fruttiger M: Intraretinal pigmented  
495 cells in retinal degenerative disease. *Br J Ophthalmol* 2023, 107(11):1736-1743.
- 496 4. Miura M, Makita S, Sugiyama S, Hong YJ, Yasuno Y, Elsner AE, Tamiya S, Tsukahara R, Iwasaki T,  
497 Goto H: Evaluation of intraretinal migration of retinal pigment epithelial cells in age-related  
498 macular degeneration using polarimetric imaging. *Sci Rep* 2017, 7(1):3150.
- 499 5. Leung I, Sallo FB, Bonelli R, Clemons TE, Pauleikhoff D, Chew EY, Bird AC, Peto T, MacTel Study G:  
500 Characteristics of Pigmented Lesions in Type 2 Idiopathic Macular Telangiectasia. *Retina* 2018,  
501 38 Suppl 1:S43-S50.
- 502 6. Tamiya S, Liu L, Kaplan HJ: Epithelial-mesenchymal transition and proliferation of retinal  
503 pigment epithelial cells initiated upon loss of cell-cell contact. *Invest Ophthalmol Vis Sci* 2010,  
504 51(5):2755-2763.
- 505 7. Zhou M, Geathers JS, Grillo SL, Weber SR, Wang W, Zhao Y, Sundstrom JM: Role of Epithelial-  
506 Mesenchymal Transition in Retinal Pigment Epithelium Dysfunction. *Front Cell Dev Biol* 2020,  
507 8:501.
- 508 8. Charbel Issa P, Gillies MC, Chew EY, Bird AC, Heeren TF, Peto T, Holz FG, Scholl HP: Macular  
509 telangiectasia type 2. *Prog Retin Eye Res* 2013, 34:49-77.
- 510 9. Tzaridis S, Heeren, Tjebo F.C., Mai, Clarissa, Thiele, Sarah, Holz, Frank G, Charbel Issa, Peter,  
511 Herrmann, Philipp: Right-angled vessels in macular telangiectasia type 2. *Br J Ophthalmol (in*  
512 *press)* 2019.
- 513 10. Tzaridis S, Wintergerst MWM, Mai C, Heeren TFC, Holz FG, Charbel Issa P, Herrmann P:  
514 Quantification of Retinal and Choriocapillaris Perfusion in Different Stages of Macular  
515 Telangiectasia Type 2. *Invest Ophthalmol Vis Sci* 2019, 60(10):3556-3562.
- 516 11. Breazzano MP, Yannuzzi LA, Spaide RF: Characterizing Retinal-Choroidal Anastomosis in Macular  
517 Telangiectasia Type 2 with Optical Coherence Tomography Angiography. *Retina* 2020, 40(1):92-  
518 98.
- 519 12. Breazzano MP, Yannuzzi LA, Spaide RF: Genesis of Retinal-Choroidal Anastomosis in Macular  
520 Telangiectasia Type 2: A Longitudinal Analysis. *Retina* 2020.
- 521 13. Gass JD, Blodi BA: Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and  
522 follow-up study. *Ophthalmology* 1993, 100(10):1536-1546.

- 523 14. Engelbrecht NE, Aaberg TM, Jr., Sung J, Lewis ML: Neovascular membranes associated with  
524 idiopathic juxtafoveal telangiectasis. *Arch Ophthalmol* 2002, 120(3):320-324.
- 525 15. Davidorf FH, Pressman MD, Chambers RB: Juxtafoveal telangiectasis-a name change? *Retina*  
526 2004, 24(3):474-478.
- 527 16. Heeren TFC, Chew EY, Clemons T, Fruttiger M, Balaskas K, Schwartz R, Egan CA, Charbel Issa P,  
528 MacTel Study G: Macular Telangiectasia Type 2: Visual Acuity, Disease End Stage, and the  
529 MacTel Area: MacTel Project Report Number 8. *Ophthalmology* 2020.
- 530 17. Mueller S, Gunnemann F, Rothaus K, Book M, Faatz H, Bird A, Pauleikhoff D: Incidence and  
531 phenotypical variation of outer retina-associated hyperreflectivity in macular telangiectasia type  
532 2. *Br J Ophthalmol* 2021, 105(4):573-576.
- 533 18. Heckenlively JR, Hawes NL, Friedlander M, Nusinowitz S, Hurd R, Davisson M, Chang B: Mouse  
534 model of subretinal neovascularization with choroidal anastomosis. *Retina* 2003, 23(4):518-522.
- 535 19. Hu W, Jiang A, Liang J, Meng H, Chang B, Gao H, Qiao X: Expression of VLDLR in the retina and  
536 evolution of subretinal neovascularization in the knockout mouse model's retinal angiomas  
537 proliferation. *Invest Ophthalmol Vis Sci* 2008, 49(1):407-415.
- 538 20. Augustin M, Fialova S, Himmel T, Glosmann M, Lengheimer T, Harper DJ, Plasenzotti R, Pircher  
539 M, Hitzenberger CK, Baumann B: Multi-Functional OCT Enables Longitudinal Study of Retinal  
540 Changes in a VLDLR Knockout Mouse Model. *PLoS One* 2016, 11(10):e0164419.
- 541 21. Dorrell MI, Aguilar E, Jacobson R, Yanes O, Gariano R, Heckenlively J, Banin E, Ramirez GA, Gasmi  
542 M, Bird A *et al*: Antioxidant or neurotrophic factor treatment preserves function in a mouse  
543 model of neovascularization-associated oxidative stress. *J Clin Invest* 2009, 119(3):611-623.
- 544 22. Sun Y, Lin Z, Liu CH, Gong Y, Liegl R, Fredrick TW, Meng SS, Burnim SB, Wang Z, Akula JD *et al*:  
545 Inflammatory signals from photoreceptor modulate pathological retinal angiogenesis via c-Fos. *J*  
546 *Exp Med* 2017, 214(6):1753-1767.
- 547 23. Li C, Huang Z, Kingsley R, Zhou X, Li F, Parke DW, II, Cao W: Biochemical Alterations in the  
548 Retinas of Very Low-Density Lipoprotein Receptor Knockout Mice: An Animal Model of Retinal  
549 Angiomas Proliferation. *Archives of Ophthalmology* 2007, 125(6):795-803.
- 550 24. Chen HC, Zhu YT, Chen SY, Tseng SC: Wnt signaling induces epithelial-mesenchymal transition  
551 with proliferation in ARPE-19 cells upon loss of contact inhibition. *Lab Invest* 2012, 92(5):676-  
552 687.
- 553 25. Matsuda Y, Nonaka Y, Futakawa S, Imai H, Akita K, Nishihata T, Fujiwara M, Ali Y, Bhisitkul RB,  
554 Nakamura Y: Anti-Angiogenic and Anti-Scarring Dual Action of an Anti-Fibroblast Growth Factor  
555 2 Aptamer in Animal Models of Retinal Disease. *Mol Ther Nucleic Acids* 2019, 17:819-828.
- 556 26. Schultz GS, Grant MB: Neovascular growth factors. *Eye (Lond)* 1991, 5 ( Pt 2):170-180.
- 557 27. Wang CH, Cao GF, Jiang Q, Yao J: TNF-alpha promotes human retinal pigment epithelial (RPE)  
558 cell migration by inducing matrix metalloproteinase 9 (MMP-9) expression through activation of  
559 Akt/mTORC1 signaling. *Biochem Biophys Res Commun* 2012, 425(1):33-38.
- 560 28. Ni Y, Qin Y, Huang Z, Liu F, Zhang S, Zhang Z: Distinct Serum and Vitreous Inflammation-Related  
561 Factor Profiles in Patients with Proliferative Vitreoretinopathy. *Adv Ther* 2020, 37(5):2550-2559.
- 562 29. Limb GA, Alam A, Earley O, Green W, Chignell AH, Dumonde DC: Distribution of cytokine  
563 proteins within epiretinal membranes in proliferative vitreoretinopathy. *Curr Eye Res* 1994,  
564 13(11):791-798.
- 565 30. Boles NC, Fernandes M, Swigut T, Srinivasan R, Schiff L, Rada-Iglesias A, Wang Q, Saini JS, Kiehl T,  
566 Stern JH *et al*: Epigenomic and Transcriptomic Changes During Human RPE EMT in a Stem Cell  
567 Model of Epiretinal Membrane Pathogenesis and Prevention by Nicotinamide. *Stem Cell Reports*  
568 2020, 14(4):631-647.



- 569 31. Meleth AD, Toy BC, Nigam D, Agron E, Murphy RP, Chew EY, Wong WT: Prevalence and  
570 progression of pigment clumping associated with idiopathic macular telangiectasia type 2.  
571 *Retina* 2013, 33(4):762-770.
- 572 32. Krivosic V, Lavia C, Aubineau A, Tadayoni R, Gaudric A: OCT of Outer Retinal Hyperreflectivity,  
573 Neovascularization, and Pigment in Macular Telangiectasia Type 2. *Ophthalmol Retina* 2021,  
574 5(6):562-570.
- 575 33. Jaissle GB, May CA, van de Pavert SA, Wenzel A, Claes-May E, Giessel A, Szurman P, Wolfrum U,  
576 Wijnholds J, Fischer MD *et al*: Bone spicule pigment formation in retinitis pigmentosa: insights  
577 from a mouse model. *Graefes Arch Clin Exp Ophthalmol* 2010, 248(8):1063-1070.
- 578 34. Pei D, Shu X, Gassama-Diagne A, Thiery JP: Mesenchymal-epithelial transition in development  
579 and reprogramming. *Nat Cell Biol* 2019, 21(1):44-53.
- 580 35. Yao D, Dai C, Peng S: Mechanism of the mesenchymal-epithelial transition and its relationship  
581 with metastatic tumor formation. *Mol Cancer Res* 2011, 9(12):1608-1620.
- 582 36. Usui-Ouchi A, Usui Y, Kurihara T, Aguilar E, Dorrell MI, Ideguchi Y, Sakimoto S, Bravo S,  
583 Friedlander M: Retinal microglia are critical for subretinal neovascular formation. *JCI Insight*  
584 2020, 5(12).
- 585 37. Chen Q, Jiang N, Zhang Y, Ye S, Liang X, Wang X, Lin X, Zong R, Chen H, Liu Z: Fenofibrate Inhibits  
586 Subretinal Fibrosis Through Suppressing TGF-beta-Smad2/3 signaling and Wnt signaling in  
587 Neovascular Age-Related Macular Degeneration. *Front Pharmacol* 2020, 11:580884.
- 588 38. Eade KT, Ansell BRE, Giles S, Fallon R, Harkins-Perry S, Nagasaki T, Tzaridis S, Wallace M, Mills EA,  
589 Farashi S *et al*: iPSC-derived retinal pigmented epithelial cells from patients with macular  
590 telangiectasia show decreased mitochondrial function. *J Clin Invest* 2023, 133(9).
- 591 39. Tzaridis S, Friedlander M, Macular Telangiectasia Type 2-Phase CRG: Functional Relevance of  
592 Hyper-Reflectivity in Macular Telangiectasia Type 2. *Invest Ophthalmol Vis Sci* 2021, 62(3):6.
- 593 40. Barth T, Zeman F, Helbig H, Gamulescu MA: Intravitreal anti-VEGF treatment for subretinal  
594 neovascularisation secondary to type 2 idiopathic juxtafoveolar telangiectasia. *Int Ophthalmol*  
595 2018, 38(1):191-198.
- 596 41. Charbel Issa P, Finger RP, Kruse K, Baumuller S, Scholl HP, Holz FG: Monthly ranibizumab for  
597 nonproliferative macular telangiectasia type 2: a 12-month prospective study. *Am J Ophthalmol*  
598 2011, 151(5):876-886 e871.
- 599 42. Kupitz EH, Heeren TF, Holz FG, Charbel Issa P: Poor Long-Term Outcome of Anti-Vascular  
600 Endothelial Growth Factor Therapy in Nonproliferative Macular Telangiectasia Type 2. *Retina*  
601 2015, 35(12):2619-2626.
- 602 43. Clemons TE, Gillies MC, Chew EY, Bird AC, Peto T, Figueroa MJ, Harrington MW, MacTel  
603 Research G: Baseline characteristics of participants in the natural history study of macular  
604 telangiectasia (MacTel) MacTel Project Report No. 2. *Ophthalmic Epidemiol* 2010, 17(1):66-73.
- 605 44. Tzaridis S, Hess K, Heeren TFC, Bonelli R, Holz FG, Friedlander M: Hyper-reflectivity on optical  
606 coherence tomography in macular telangiectasia type 2. *Retina* 2021.
- 607 45. Li C, Huang Z, Kingsley R, Zhou X, Li F, Parke DW, 2nd, Cao W: Biochemical alterations in the  
608 retinas of very low-density lipoprotein receptor knockout mice: an animal model of retinal  
609 angiomatous proliferation. *Arch Ophthalmol* 2007, 125(6):795-803.

610

611

612 **Figures and legends**

613 **Figure 1:** Perivascular accumulation of pigment plaques decreases vascular leakage in  
614 patients with MacTel.

615 Longitudinal courses of three exemplary eyes showing a *de novo* formation of  
616 perivascular pigment plaques, imaged with color fundus photography (CFP), blue-light  
617 autofluorescence (BAF), and fundus fluorescein angiography (FFA; early to  
618 intermediate phase and late phase). A decrease in fluorescein leakage can be observed  
619 in vessels covered with pigment (yellow borderline), while vessels lacking pigment may  
620 show an increase in leakage and proliferation (blue borderline). The right column  
621 illustrates enlarged BAF and FFA images of case #2 within the temporal and nasal  
622 parafovea, respectively.

623

624 **Figure 2:** Perivascular pigment accumulation stabilizes vessel growth and decreases  
625 neovascular exudation in eyes with MacTel.

626 Longitudinal courses of exemplary eyes with (cases 1-3) and without (cases 4-6) a *de*  
627 *novo* development of pigment plaques. Perivascular pigment accumulation is  
628 associated with a decrease in fluorescein leakage on fundus fluorescein angiography  
629 (FFA), and overall stable findings on spectral domain-optical coherence tomography  
630 (SD-OCT). Note the increase in intraretinal hyper-reflectivity (black arrowheads) with  
631 shadowing of underlying structures (white arrowheads) associated with pigment  
632 accumulation. Eyes without pigmentary changes show an increase in fluorescein  
633 leakage that may be associated with the *de novo* development of exudative

634 neovascularization (white arrowheads). Hemorrhages may occur. CFP: color fundus  
635 photography.

636

637 **Figure 3:** The Vldlr knockout mouse model mirrors vascular and pigmentary changes  
638 observed in MacTel.

639 A: Proliferating vessels trigger perivascular pigment accumulation in Vldlr<sup>-/-</sup> mice.

640 Neovascular (NV) tufts and perivascular pigment accumulation were analyzed using

641 GS-lectin staining and bright field images in P28 Vldlr<sup>-/-</sup> mice treated with intravitreal

642 injections of anti-VEGF (n=6) or control IgG (n=4) at P12. While anti-VEGF treatment

643 significantly decreased the total number of NV-tufts (Mann-Whitney test, \*p=0.019), the

644 ratio of pigmented to non-pigmented NV-tufts was unchanged. Pigment plaques only

645 developed along proliferating vessels. Error bars indicate the median and interquartile

646 range. B: Regulation of different genes coding for key molecules and inducers of

647 epithelial-mesenchymal transition (EMT) in the retina and RPE of Vldlr<sup>-/-</sup> mice at P42.

648 Changes in genes between Vldlr<sup>-/-</sup> and Vldlr<sup>+/-</sup> mice, as analyzed using a PCR array

649 for EMT, are shown. P values were calculated based on a Mann-Whitney test of the

650 replicate 2(-Delta Ct) values for each gene in the Vldlr<sup>-/-</sup> and Vldlr<sup>+/-</sup> groups. \*P < 0.05,

651 \*\*P < 0.01 (n=5 each). Median and IQR are shown for each gene. C: Dextran-

652 angiography in a 12-months-old Vldlr<sup>-/-</sup> mouse depicts vessel and pigment proliferation

653 and migration of pigmented cells along retinal vessels. Vessels covered with pigment

654 show reduced dextran leakage (enlarged images, yellow arrowheads) compared to

655 vessels not covered with pigment (white arrowheads). D: Pigment plaques cover

656 proliferating vessels (stained with GS-lectin) and express ZO-1, indicating the formation

657 of tight junctions along subretinal and retinal vessels in eyes of 10-months-old Vldlr<sup>-/-</sup>  
658 mice. E: Vldlr knockout (vldlr<sup>-/-</sup>) mice show hyper-reflective changes at the level of the  
659 outer retina (yellow arrowheads)/ retinal pigment epithelium (RPE; black arrowheads)  
660 on optical coherence tomography that resemble alterations observed in MacTel.

661 **Figure 4:** Inhibition of epithelial-mesenchymal-transition (EMT) leads to enhanced  
662 neovascular proliferation and leak in the Vldlr<sup>-/-</sup> model.

663 A-C: Dextran angiography and GS lectin staining in flat mounted (A, upper panel) or  
664 cryo-sectioned (A, middle and lower panel) Vldlr<sup>-/-</sup> mice treated with intravitreal  
665 injections of neutralizing antibodies against TNF $\alpha$  (n=7) or FGF2 (n=7) at P21 showed a  
666 significant increase in dextran leakage (A, upper panel; C), and a significant increase in  
667 size of neovascular (NV) complexes (B) at P42 compared to IgG-treated controls (n=7).  
668 Yellow-dotted boxes in A (upper panel) show enlarged neovascular complexes in  
669 treated eyes.

670 GS-lectin staining and bright field images of cryo-sectioned Vldlr<sup>-/-</sup> (A, middle and lower  
671 panel) illustrate decreased pigment proliferation and perivascular accumulation in eyes  
672 treated with anti-TNF $\alpha$  or anti-FGF2. D: Dextran-leakage (number of pixels positive for  
673 dextran) was negatively correlated (Pearson  $r=-0.78$ ;  $p<0.0001$ ) with pigment  
674 accumulation (number of pixels positive for pigment) in flat-mounted Vldlr<sup>-/-</sup> eyes. E and  
675 F: Changes in genes coding for key molecules of EMT in Vldlr<sup>-/-</sup> mice at P42 treated  
676 with either anti-TNF $\alpha$  (E) or anti-FGF2 (F) compared to IgG-treated Vldlr<sup>-/-</sup> mice  
677 (treatment at P21), as analyzed using a PCR array for EMT, are shown. While  
678 mesenchymal key molecules (white bars) were downregulated, epithelial key molecules

679 were enriched (grey bars). P values were calculated based on a Mann-Whitney test of  
680 the replicate 2(-Delta Ct) values for each gene. \*P < 0.05, \*\*P < 0.01 (n = 4 each).

681 Figure 5: Schematic illustration of the proposed interplay between RPE-cells and retinal  
682 vessels in the Vldlr<sup>-/-</sup> model.

683 A: Proliferating vessels of the deep retinal plexus grow to the outer retina, form  
684 neovascular tufts and get in contact with the RPE. RPE-cells transition from an epithelial  
685 to a mesenchymal state, proliferate and migrate along retinal vessels into the  
686 neuroretina, forming perivascular plaques.

687 B: Eyes treated with intravitreal antibodies against VEGF (anti-VEGF) show a reduction  
688 in vessel proliferation and decreased numbers of neovascular tufts, while EMT of the  
689 RPE is not impacted.

690 C: In eyes treated with intravitreal antibodies against TNF $\alpha$  or FGF2, epithelial-  
691 mesenchymal transition (EMT) of the RPE is inhibited. RPE cells show reduced  
692 proliferation, perivascular accumulation and migration. Neovascular tufts show more  
693 leakage and increased lateral growth.

694 Created with BioRender.com

695

696 Table 1: Clinical findings in the study cohort of patients with macular telangiectasia type  
697 2 (MacTel).

	<b>Pigment plaques</b>	<b>No pigment plaques</b>	<b>Statistical significance</b>
<b>Eyes</b>	35 [51%]	34 [49%]	ns*

<b>Follow up period (months; mean [range])</b>	41 [24-60]	39 [24-60]	ns*
<b>Fluorescein leakage temporal parafovea (ETDRS subfield 5)</b>			
<b>Increase</b>	1 [3%]	16 [47%]	p<0.0001**
<b>Decrease</b>	34 [97%]	0	NA
<b>Stable</b>	0	18 [53%]	NA
<b>Exudative neovascularization</b>	1 [3%]	7 [21%]	p=0.0275**
<b>Visual acuity: Loss of letters/year (mean [SD])</b>	1.1 [2.3]	3.1 [3.9]	p=0.0125*

698

699 \*p-values were calculated based on an unpaired t-test with Welch's correction.

700 \*\*p-values were calculated based on a Fisher's exact test.

701

702

703 **Supplement:**

704 Supplementary Figure 1: Pigment accumulates along proliferating retinal vessels and  
705 retinal-choroidal anastomoses in eyes with MacTel.

706 Multimodal retinal images of four exemplary eyes with MacTel, including optical  
707 coherence tomography-angiography (enface scans of the following layers are shown:  
708 whole retina, superficial retinal plexus, deep retinal plexus and whole eye scans;  
709 vessels forming retinal-retinal and retinal-choroidal anastomoses are marked in red), B-  
710 scan Spectral domain (SD-) OCT, color fundus photographs (CFP), blue-light  
711 autofluorescence (BAF), and fundus fluorescein angiograms (FFA, late phase). Pigment  
712 plaques are indicated with arrow heads. On OCT, pigment plaques depict as hyper-  
713 reflective lesions. Horizontal lines on CFP images indicate the position of each B-scan.

714

715 Supplementary Figure 2: Dense intraretinal pigment plaques express the retinal pigment  
716 epithelium marker Cytokeratin-18 (CK-18).

717 Immunofluorescence imaging of retinal sections of 11-months-old *Vldlr*<sup>-/-</sup> mice with GS-  
718 lectin (red) and CK-18, alpha-smooth muscle actin ( $\alpha$ -SMA), IBA-1 or RPE65 (green).  
719 Nuclei are shown in blue (DAPI). Intraretinal pigment co-locates with CK-18, but not with  
720  $\alpha$ -SMA, IBA1 or RPE65.

721

722 Supplementary Figure 3: RPE-cells form clusters around neovessels within the  
723 subretinal space, and express epithelial and mesenchymal markers.

724 Dense intraretinal pigment plaques (along vessels of the deep plexus) express the RPE  
725 marker Cytokeratin-18 (CK-18), but not RPE65. The expression of  $\alpha$ -SMA was  
726 observed in single pigmented intraretinal lesions (black arrowhead). The latter  
727 appeared, however, overall less dense compared to those lesions lacking  $\alpha$ -SMA  
728 expression (white arrowhead). Immunofluorescence imaging of flat mounted retinas of  
729 12-months-old Vldlr<sup>-/-</sup> mice with GS-lectin (red) and CK-18, alpha-smooth muscle actin  
730 ( $\alpha$ -SMA), IBA-1 or RPE65 (green). Nuclei are shown in blue (DAPI).




731



732








733




734












Natural disease progression




A

Inhibition of vascular proliferation



B

Inhibition of EMT



or



C